Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ANK-101 |
| Trade Name | |
| Synonyms | ANK 101|ANK101|Tolododekin Alfa |
| Drug Descriptions |
ANK-101 consists of an IL-12 variant linked to an alum-binding peptide and complexed with aluminium hydroxide, which potentially enhances antitumor immune response and reduces tumor growth (PMID: 38063196). |
| DrugClasses | |
| CAS Registry Number | 3028474-00-9 |
| NCIT ID | C203514 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ANK-101 | ANK-101 | 0 | 2 |
| ANK-101 + Cetrelimab | ANK-101 Cetrelimab | 0 | 1 |